SEC Comment Letter 0000000000-24-011170 to AYTU BIOPHARMA, INC (AYTU)
AYTU BIOPHARMA, INC
Date: Oct. 3, 2024 · CIK: 0001385818 · Accession: 0000000000-24-011170
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282347
Letter
October 3, 2024 Joshua R. Disbrow Chairman and Chief Executive Officer Aytu BioPharma, Inc. 7900 East Union Avenue, Suite 920 Denver, CO 80237 Re:Aytu BioPharma, Inc. Registration Statement on Form S-3 Filed September 26, 2024 File No. 333-282347 Dear Joshua R. Disbrow: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Anthony Epps, Esq.
Show Raw Text
October 3, 2024
Joshua R. Disbrow
Chairman and Chief Executive Officer
Aytu BioPharma, Inc.
7900 East Union Avenue, Suite 920
Denver, CO 80237
Re:Aytu BioPharma, Inc.
Registration Statement on Form S-3
Filed September 26, 2024
File No. 333-282347
Dear Joshua R. Disbrow:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Anthony Epps, Esq.